# Clinical efficacy of probiotics in improving intestinal mucosal permeability for functional dyspepsia patients with anxiety

**Authors:** Kang-ming Huang, Hua-bin Qiu, Dong-ping Liao, Ya-yue Jiang, Ying-Han Deng, Hong-bin Chen

PMC · DOI: 10.3389/fmicb.2025.1614705 · 2025-06-18

## TL;DR

Probiotics help reduce symptoms and anxiety in patients with functional dyspepsia by improving intestinal permeability.

## Contribution

This study demonstrates probiotics' efficacy in improving intestinal permeability and anxiety in functional dyspepsia patients.

## Key findings

- Probiotics significantly reduced inflammation markers and anxiety scores in FD patients with anxiety.
- Changes in intestinal permeability markers were linked to symptom and anxiety improvement.
- Probiotic intervention was strongly associated with symptom relief in FD patients with anxiety.

## Abstract

The aim of this study was to investigate whether probiotics are effective in improving symptoms of functional dyspepsia (FD) accompanied by anxiety.

There were 116 patients with FD accompanied by anxiety and 114 patients without anxiety. Each group was randomly divided into an intervention group and a control group. The intervention group received probiotics in addition to conventional acid suppression and gastric protection, as well as prokinetic treatments. The control group received conventional treatment plus a placebo.

Before treatment, significant differences were observed in IL-1, IL-6, TNF-α, LPS, Zonulin, DAO, and I-FABP between patients with FD accompanied by anxiety and those without anxiety (p < 0.05). Following the intervention with probiotics, the group with FD and anxiety experienced significant decreases in IL-1, IL-6, TNF-α, LPS, Zonulin, and DAO (p < 0.001), as well as significant reductions in the Patient Assessment of Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM) and the Hamilton Anxiety Scale (HAMA) scores (p < 0.001). In contrast, the intervention group with FD but without anxiety had significant reductions in IL-6 and TNF-α (p < 0.05), along with a significant decrease in the PAGI-SYM score (p < 0.001). Binary logistic regression analysis further revealed that lower I-FABP values (OR = 0.999, p = 0.036), lower LPS values (OR = 0.998, p = 0.013), and probiotic intervention (OR = 5.138, p = 0.000) were significantly associated with symptom relief.

The intervention significantly improved the symptoms and anxiety scores of patients with FD and anxiety, and the changes in intestinal mucosal permeability indexes were closely related to symptom relief and anxiety improvement, Probiotic interventions may be an effective means of improving symptoms in patients with FD.

identifier ChiCTR2300077847 https://www.chictr.org.cn/.

## Linked entities

- **Proteins:** IL1A (interleukin 1 alpha), IL6 (interleukin 6), TNF (tumor necrosis factor), IRF6 (interferon regulatory factor 6), Hp (haptoglobin), DAO (D-amino acid oxidase), FABP2 (fatty acid binding protein 2)
- **Diseases:** anxiety (MONDO:0005618)

## Full-text entities

- **Genes:** SYMPK (symplekin scaffold protein) [NCBI Gene 8189] {aka Pta1, SPK, SYM}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, HP (haptoglobin) [NCBI Gene 3240] {aka HP2ALPHA2, HPA1S}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, FABP2 (fatty acid binding protein 2) [NCBI Gene 2169] {aka FABPI, I-FABP}
- **Diseases:** Anxiety (MESH:D001007), FD (MESH:D004415), Gastrointestinal Disorders (MESH:D005767)
- **Chemicals:** LPS (MESH:D008070), DAO (MESH:C030358)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12215697/full.md

---
Source: https://tomesphere.com/paper/PMC12215697